BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:17 PM
 | 
Sep 28, 2012
 |  BC Extra  |  Company News

Aveo seeks approval of tivozanib for RCC

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) submitted an NDA to FDA for tivozanib to treat advanced renal cell carcinoma (RCC). The NDA is based on data from the Phase III TIVO-1 trial, which showed that tivozanib met the primary endpoint...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >